Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12-30

AUTHORS

Fadi Farhat, Ahmad Othman, Fadi el Karak, Joseph Kattan

ABSTRACT

BackgroundOnly drafts of regulatory guidelines for the registration of biosimilars are available in Lebanon. We analyzed the results of a regional survey conducted in Lebanon to understand the impact of different parameters on the acceptance and future prescription of biosimilars. We also reviewed the current situation of biosimilars around the world. The study surveyed healthcare professionals from the Arab countries, Iran, Belgium and Italy. Data about the participants’ specialty, country of residence, their knowledge about biosimilars, biosimilars’ prescription, price influence and the manufacturer’s credibility were collected.Results117 questionnaires were completed and returned: 46 (39.3%) respondents were oncologists. 72 (61.5%) respondents were Lebanese, and the others from Egypt, Syria, Algeria, Iraq, Sudan, Jordan, Iran, Belgium and Italy. 77 (65.8%) respondents had knowledge about biosimilars, of whom 48 (62.3%) considered biosimilars as biologics that demonstrate bioequivalence with the original biodrug and have all preclinical and clinical trials equal to those already performed with the original biodrug. 74 (63.2%) out of 117 respondents agreed that biosimilars in the Arab and Middle Eastern market are already marketed. Among the 48 participants who prescribe biosimilars, the main prescription driver was the drug’s approval by the FDA and EMA (68.8%). 71 (60.7%) respondents considered that the main advantage of biosimilars is their lower price and 41 (35%) out of the 117 respondents declared that they should know in which country the drug has been tested/created before using it in their own country. 35% of the respondents thought that the cost of a treatment should not come before its effectiveness or safety/tolerance, given that the biosimilar will be less expensive than the reference drug.ConclusionsBiosimilars’ acceptance and use is increasing worldwide. Only few physicians are aware of biosimilars presence in the market and do prescribe them in Lebanon and the Arab region. This could be mainly explained by lack of confidence in efficacy, safety, manufacturing process and price of these products, and lack of clear legislation. Thus, WHO is finalizing a new guideline for similar biotherapeutic agents. This could be a starting point for the Lebanese government to support the authorization of biosimilars. More... »

PAGES

2113

References to SciGraph publications

  • 2011-05-16. Market access of biosimilars: not only a cost issue in ONCOLOGIE
  • 2013-09-11. Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners in CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS
  • 2012-06. The US Biosimilars Act in PHARMACEUTICAL MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s40064-016-3779-8

    DOI

    http://dx.doi.org/10.1186/s40064-016-3779-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1005712339

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28090427


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Faculty of Medicine, Saint Joseph University, Beirut, Lebanon", 
              "id": "http://www.grid.ac/institutes/grid.42271.32", 
              "name": [
                "Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon", 
                "Faculty of Medicine, Saint Joseph University, Beirut, Lebanon"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Farhat", 
            "givenName": "Fadi", 
            "id": "sg:person.01054414767.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054414767.72"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon", 
              "id": "http://www.grid.ac/institutes/grid.477313.5", 
              "name": [
                "Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Othman", 
            "givenName": "Ahmad", 
            "id": "sg:person.0636371517.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636371517.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, H\u00f4tel-Dieu de France University Hospital, Beirut, Lebanon", 
              "id": "http://www.grid.ac/institutes/grid.413559.f", 
              "name": [
                "Faculty of Medicine, Saint Joseph University, Beirut, Lebanon", 
                "Department of Medical Oncology, H\u00f4tel-Dieu de France University Hospital, Beirut, Lebanon"
              ], 
              "type": "Organization"
            }, 
            "familyName": "el Karak", 
            "givenName": "Fadi", 
            "id": "sg:person.01302445146.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302445146.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, H\u00f4tel-Dieu de France University Hospital, Beirut, Lebanon", 
              "id": "http://www.grid.ac/institutes/grid.413559.f", 
              "name": [
                "Faculty of Medicine, Saint Joseph University, Beirut, Lebanon", 
                "Department of Medical Oncology, H\u00f4tel-Dieu de France University Hospital, Beirut, Lebanon"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kattan", 
            "givenName": "Joseph", 
            "id": "sg:person.01142356070.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142356070.00"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf03262388", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033306008", 
              "https://doi.org/10.1007/bf03262388"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10269-011-2018-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018312966", 
              "https://doi.org/10.1007/s10269-011-2018-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40138-013-0023-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051012823", 
              "https://doi.org/10.1007/s40138-013-0023-5"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-12-30", 
        "datePublishedReg": "2016-12-30", 
        "description": "BackgroundOnly drafts of regulatory guidelines for the registration of biosimilars are available in Lebanon. We analyzed the results of a regional survey conducted in Lebanon to understand the impact of different parameters on the acceptance and future prescription of biosimilars. We also reviewed the current situation of biosimilars around the world. The study surveyed healthcare professionals from the Arab countries, Iran, Belgium and Italy. Data about the participants\u2019 specialty, country of residence, their knowledge about biosimilars, biosimilars\u2019 prescription, price influence and the manufacturer\u2019s credibility were collected.Results117 questionnaires were completed and returned: 46 (39.3%) respondents were oncologists. 72 (61.5%) respondents were Lebanese, and the others from Egypt, Syria, Algeria, Iraq, Sudan, Jordan, Iran, Belgium and Italy. 77 (65.8%) respondents had knowledge about biosimilars, of whom 48 (62.3%) considered biosimilars as biologics that demonstrate bioequivalence with the original biodrug and have all preclinical and clinical trials equal to those already performed with the original biodrug. 74 (63.2%) out of 117 respondents agreed that biosimilars in the Arab and Middle Eastern market are already marketed. Among the 48 participants who prescribe biosimilars, the main prescription driver was the drug\u2019s approval by the FDA and EMA (68.8%). 71 (60.7%) respondents considered that the main advantage of biosimilars is their lower price and 41 (35%) out of the 117 respondents declared that they should know in which country the drug has been tested/created before using it in their own country. 35% of the respondents thought that the cost of a treatment should not come before its effectiveness or safety/tolerance, given that the biosimilar will be less expensive than the reference drug.ConclusionsBiosimilars\u2019 acceptance and use is increasing worldwide. Only few physicians are aware of biosimilars presence in the market and do prescribe them in Lebanon and the Arab region. This could be mainly explained by lack of confidence in efficacy, safety, manufacturing process and price of these products, and lack of clear legislation. Thus, WHO is finalizing a new guideline for similar biotherapeutic agents. This could be a starting point for the Lebanese government to support the authorization of biosimilars.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s40064-016-3779-8", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1047790", 
            "issn": [
              "2193-1801"
            ], 
            "name": "SpringerPlus", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "5"
          }
        ], 
        "keywords": [
          "biosimilar prescriptions", 
          "safety/tolerance", 
          "clinical trials", 
          "healthcare professionals", 
          "biotherapeutic agents", 
          "reference drug", 
          "drug approval", 
          "prescription", 
          "participant's specialty", 
          "new guidelines", 
          "biosimilars", 
          "drugs", 
          "lack of confidence", 
          "future prescription", 
          "approval", 
          "biodrugs", 
          "guidelines", 
          "specialties", 
          "respondents", 
          "oncologists", 
          "regulatory guidelines", 
          "country of residence", 
          "physicians", 
          "trials", 
          "biologics", 
          "efficacy", 
          "bioequivalence", 
          "FDA", 
          "treatment", 
          "EMA", 
          "questionnaire", 
          "lack", 
          "Iran", 
          "participants", 
          "safety", 
          "survey", 
          "review", 
          "professionals", 
          "residence", 
          "agents", 
          "Lebanon", 
          "countries", 
          "acceptance", 
          "Africa region", 
          "study", 
          "Belgium", 
          "knowledge", 
          "Arab countries", 
          "North Africa (MENA) region", 
          "Italy", 
          "regional survey", 
          "tolerance", 
          "presence", 
          "results", 
          "Sudan", 
          "use", 
          "registration of biosimilars", 
          "registration", 
          "data", 
          "region", 
          "effectiveness", 
          "Middle East", 
          "impact", 
          "confidence", 
          "clear legislation", 
          "authorization", 
          "challenges", 
          "Jordan", 
          "Iraq", 
          "Arab region", 
          "Egypt", 
          "current situation", 
          "point", 
          "situation", 
          "influence", 
          "products", 
          "cost", 
          "parameters", 
          "world", 
          "advantages", 
          "starting point", 
          "drivers", 
          "process", 
          "credibility", 
          "Algeria", 
          "different parameters", 
          "own country", 
          "legislation", 
          "draft", 
          "main advantage", 
          "Syria", 
          "East", 
          "low price", 
          "government", 
          "Lebanese government", 
          "market", 
          "prices", 
          "manufacturing process", 
          "price influence", 
          "Eastern markets", 
          "Middle Eastern markets"
        ], 
        "name": "Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region", 
        "pagination": "2113", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1005712339"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s40064-016-3779-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28090427"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s40064-016-3779-8", 
          "https://app.dimensions.ai/details/publication/pub.1005712339"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:00", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_713.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s40064-016-3779-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3779-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3779-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3779-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3779-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    202 TRIPLES      21 PREDICATES      129 URIs      118 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s40064-016-3779-8 schema:about anzsrc-for:11
    2 anzsrc-for:1117
    3 schema:author N9980321b80654fc18c6d7b2c5f613576
    4 schema:citation sg:pub.10.1007/bf03262388
    5 sg:pub.10.1007/s10269-011-2018-8
    6 sg:pub.10.1007/s40138-013-0023-5
    7 schema:datePublished 2016-12-30
    8 schema:datePublishedReg 2016-12-30
    9 schema:description BackgroundOnly drafts of regulatory guidelines for the registration of biosimilars are available in Lebanon. We analyzed the results of a regional survey conducted in Lebanon to understand the impact of different parameters on the acceptance and future prescription of biosimilars. We also reviewed the current situation of biosimilars around the world. The study surveyed healthcare professionals from the Arab countries, Iran, Belgium and Italy. Data about the participants’ specialty, country of residence, their knowledge about biosimilars, biosimilars’ prescription, price influence and the manufacturer’s credibility were collected.Results117 questionnaires were completed and returned: 46 (39.3%) respondents were oncologists. 72 (61.5%) respondents were Lebanese, and the others from Egypt, Syria, Algeria, Iraq, Sudan, Jordan, Iran, Belgium and Italy. 77 (65.8%) respondents had knowledge about biosimilars, of whom 48 (62.3%) considered biosimilars as biologics that demonstrate bioequivalence with the original biodrug and have all preclinical and clinical trials equal to those already performed with the original biodrug. 74 (63.2%) out of 117 respondents agreed that biosimilars in the Arab and Middle Eastern market are already marketed. Among the 48 participants who prescribe biosimilars, the main prescription driver was the drug’s approval by the FDA and EMA (68.8%). 71 (60.7%) respondents considered that the main advantage of biosimilars is their lower price and 41 (35%) out of the 117 respondents declared that they should know in which country the drug has been tested/created before using it in their own country. 35% of the respondents thought that the cost of a treatment should not come before its effectiveness or safety/tolerance, given that the biosimilar will be less expensive than the reference drug.ConclusionsBiosimilars’ acceptance and use is increasing worldwide. Only few physicians are aware of biosimilars presence in the market and do prescribe them in Lebanon and the Arab region. This could be mainly explained by lack of confidence in efficacy, safety, manufacturing process and price of these products, and lack of clear legislation. Thus, WHO is finalizing a new guideline for similar biotherapeutic agents. This could be a starting point for the Lebanese government to support the authorization of biosimilars.
    10 schema:genre article
    11 schema:isAccessibleForFree true
    12 schema:isPartOf N25cf45ccb6a1419c9fff1cc6ea2f2e1f
    13 N922f578380c3490eab84f81674260991
    14 sg:journal.1047790
    15 schema:keywords Africa region
    16 Algeria
    17 Arab countries
    18 Arab region
    19 Belgium
    20 EMA
    21 East
    22 Eastern markets
    23 Egypt
    24 FDA
    25 Iran
    26 Iraq
    27 Italy
    28 Jordan
    29 Lebanese government
    30 Lebanon
    31 Middle East
    32 Middle Eastern markets
    33 North Africa (MENA) region
    34 Sudan
    35 Syria
    36 acceptance
    37 advantages
    38 agents
    39 approval
    40 authorization
    41 biodrugs
    42 bioequivalence
    43 biologics
    44 biosimilar prescriptions
    45 biosimilars
    46 biotherapeutic agents
    47 challenges
    48 clear legislation
    49 clinical trials
    50 confidence
    51 cost
    52 countries
    53 country of residence
    54 credibility
    55 current situation
    56 data
    57 different parameters
    58 draft
    59 drivers
    60 drug approval
    61 drugs
    62 effectiveness
    63 efficacy
    64 future prescription
    65 government
    66 guidelines
    67 healthcare professionals
    68 impact
    69 influence
    70 knowledge
    71 lack
    72 lack of confidence
    73 legislation
    74 low price
    75 main advantage
    76 manufacturing process
    77 market
    78 new guidelines
    79 oncologists
    80 own country
    81 parameters
    82 participant's specialty
    83 participants
    84 physicians
    85 point
    86 prescription
    87 presence
    88 price influence
    89 prices
    90 process
    91 products
    92 professionals
    93 questionnaire
    94 reference drug
    95 region
    96 regional survey
    97 registration
    98 registration of biosimilars
    99 regulatory guidelines
    100 residence
    101 respondents
    102 results
    103 review
    104 safety
    105 safety/tolerance
    106 situation
    107 specialties
    108 starting point
    109 study
    110 survey
    111 tolerance
    112 treatment
    113 trials
    114 use
    115 world
    116 schema:name Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region
    117 schema:pagination 2113
    118 schema:productId N5896695e14734f789334e5db2b458878
    119 N81a4142d926d4ccaa55c7fa568553f4a
    120 N82014586bd264297a552f7f1eafd92e0
    121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005712339
    122 https://doi.org/10.1186/s40064-016-3779-8
    123 schema:sdDatePublished 2022-09-02T16:00
    124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    125 schema:sdPublisher N9332b2717e58497eb2695c4c0084aac2
    126 schema:url https://doi.org/10.1186/s40064-016-3779-8
    127 sgo:license sg:explorer/license/
    128 sgo:sdDataset articles
    129 rdf:type schema:ScholarlyArticle
    130 N25cf45ccb6a1419c9fff1cc6ea2f2e1f schema:volumeNumber 5
    131 rdf:type schema:PublicationVolume
    132 N5896695e14734f789334e5db2b458878 schema:name dimensions_id
    133 schema:value pub.1005712339
    134 rdf:type schema:PropertyValue
    135 N5909977d9b99446da25749515ec3660b rdf:first sg:person.0636371517.53
    136 rdf:rest Na897445366294482bb8af846c91ea647
    137 N7af14dfb56a44ac6a8fcb21dab793b89 rdf:first sg:person.01142356070.00
    138 rdf:rest rdf:nil
    139 N81a4142d926d4ccaa55c7fa568553f4a schema:name doi
    140 schema:value 10.1186/s40064-016-3779-8
    141 rdf:type schema:PropertyValue
    142 N82014586bd264297a552f7f1eafd92e0 schema:name pubmed_id
    143 schema:value 28090427
    144 rdf:type schema:PropertyValue
    145 N922f578380c3490eab84f81674260991 schema:issueNumber 1
    146 rdf:type schema:PublicationIssue
    147 N9332b2717e58497eb2695c4c0084aac2 schema:name Springer Nature - SN SciGraph project
    148 rdf:type schema:Organization
    149 N9980321b80654fc18c6d7b2c5f613576 rdf:first sg:person.01054414767.72
    150 rdf:rest N5909977d9b99446da25749515ec3660b
    151 Na897445366294482bb8af846c91ea647 rdf:first sg:person.01302445146.89
    152 rdf:rest N7af14dfb56a44ac6a8fcb21dab793b89
    153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    154 schema:name Medical and Health Sciences
    155 rdf:type schema:DefinedTerm
    156 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    157 schema:name Public Health and Health Services
    158 rdf:type schema:DefinedTerm
    159 sg:journal.1047790 schema:issn 2193-1801
    160 schema:name SpringerPlus
    161 schema:publisher Springer Nature
    162 rdf:type schema:Periodical
    163 sg:person.01054414767.72 schema:affiliation grid-institutes:grid.42271.32
    164 schema:familyName Farhat
    165 schema:givenName Fadi
    166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054414767.72
    167 rdf:type schema:Person
    168 sg:person.01142356070.00 schema:affiliation grid-institutes:grid.413559.f
    169 schema:familyName Kattan
    170 schema:givenName Joseph
    171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142356070.00
    172 rdf:type schema:Person
    173 sg:person.01302445146.89 schema:affiliation grid-institutes:grid.413559.f
    174 schema:familyName el Karak
    175 schema:givenName Fadi
    176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302445146.89
    177 rdf:type schema:Person
    178 sg:person.0636371517.53 schema:affiliation grid-institutes:grid.477313.5
    179 schema:familyName Othman
    180 schema:givenName Ahmad
    181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636371517.53
    182 rdf:type schema:Person
    183 sg:pub.10.1007/bf03262388 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033306008
    184 https://doi.org/10.1007/bf03262388
    185 rdf:type schema:CreativeWork
    186 sg:pub.10.1007/s10269-011-2018-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018312966
    187 https://doi.org/10.1007/s10269-011-2018-8
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1007/s40138-013-0023-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051012823
    190 https://doi.org/10.1007/s40138-013-0023-5
    191 rdf:type schema:CreativeWork
    192 grid-institutes:grid.413559.f schema:alternateName Department of Medical Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
    193 schema:name Department of Medical Oncology, Hôtel-Dieu de France University Hospital, Beirut, Lebanon
    194 Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
    195 rdf:type schema:Organization
    196 grid-institutes:grid.42271.32 schema:alternateName Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
    197 schema:name Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon
    198 Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
    199 rdf:type schema:Organization
    200 grid-institutes:grid.477313.5 schema:alternateName Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon
    201 schema:name Department of Hematology-Oncology, Hammoud Hospital University Medical Center, G. Hammoud Street, 652, Sidon, Lebanon
    202 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...